N@N

Andreas Argyrides Maintained (ASND) at Buy with Increased Target to $187 on, Jun 2nd, 2023

Andreas Argyrides of Wedbush, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $186 to $187 on, Jun 2nd, 2023.

Andreas has made no other calls on ASND in the last 4 months.

There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 3 agree with Andreas's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Tiago Fauth of "Credit Suisse" Maintained at Hold with Increased Target to $89 on, Friday, April 28th, 2023
• Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $109 on, Friday, April 28th, 2023
• Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, April 5th, 2023

These are the ratings of the 3 analyists that currently disagree with Andreas

---

• Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $152 on, Thursday, June 1st, 2023
• David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $146 on, Wednesday, April 5th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023

Contributing Sources

---